Frontiers in Endocrinology (Apr 2023)
Relationship between stress hyperglycemia ratio and allcause mortality in critically ill patients: Results from the MIMIC-IV database
- Chong Zhang,
- Chong Zhang,
- Chong Zhang,
- Chong Zhang,
- Chong Zhang,
- He-Chen Shen,
- He-Chen Shen,
- He-Chen Shen,
- He-Chen Shen,
- He-Chen Shen,
- Wei-Ru Liang,
- Meng Ning,
- Meng Ning,
- Meng Ning,
- Meng Ning,
- Zi-Xuan Wang,
- Zi-Xuan Wang,
- Zi-Xuan Wang,
- Zi-Xuan Wang,
- Yi Chen,
- Yi Chen,
- Yi Chen,
- Yi Chen,
- Yi Chen,
- Wei Su,
- Wei Su,
- Wei Su,
- Wei Su,
- Wei Su,
- Ting-Ting Guo,
- Ting-Ting Guo,
- Ting-Ting Guo,
- Ting-Ting Guo,
- Ting-Ting Guo,
- Kun Hu,
- Kun Hu,
- Kun Hu,
- Kun Hu,
- Kun Hu,
- Ying-Wu Liu,
- Ying-Wu Liu,
- Ying-Wu Liu,
- Ying-Wu Liu,
- Ying-Wu Liu
Affiliations
- Chong Zhang
- The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- Chong Zhang
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- Chong Zhang
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- Chong Zhang
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- Chong Zhang
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- He-Chen Shen
- The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- He-Chen Shen
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- He-Chen Shen
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- He-Chen Shen
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- He-Chen Shen
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Wei-Ru Liang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
- Meng Ning
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- Meng Ning
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- Meng Ning
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- Meng Ning
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Zi-Xuan Wang
- The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- Zi-Xuan Wang
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- Zi-Xuan Wang
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- Zi-Xuan Wang
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- Yi Chen
- The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- Yi Chen
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- Yi Chen
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- Yi Chen
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- Yi Chen
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Wei Su
- The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- Wei Su
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- Wei Su
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- Wei Su
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- Wei Su
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Ting-Ting Guo
- The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- Ting-Ting Guo
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- Ting-Ting Guo
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- Ting-Ting Guo
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- Ting-Ting Guo
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Kun Hu
- The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- Kun Hu
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- Kun Hu
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- Kun Hu
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- Kun Hu
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Ying-Wu Liu
- The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- Ying-Wu Liu
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China
- Ying-Wu Liu
- Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China
- Ying-Wu Liu
- Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China
- Ying-Wu Liu
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- DOI
- https://doi.org/10.3389/fendo.2023.1111026
- Journal volume & issue
-
Vol. 14
Abstract
BackgroundStress hyperglycemia ratio (SHR) was developed to reduce the impact of long-term chronic glycemic factors on stress hyperglycemia levels, which have been linked to clinical adverse events. However, the relationship between SHR and the short- and long-term prognoses of intensive care unit (ICU) patients remains unclear.MethodsWe retrospectively analyzed 3,887 ICU patients (cohort 1) whose initial fasting blood glucose and hemoglobin A1c data within 24 hours of admission were available and 3,636 ICU patients (cohort 2) who were followed-up for 1-year using the Medical Information Mart for Intensive Care IV v2.0 database. Patients were divided into two groups based on the optimal cutoff value of SHR, which was determined using the receiver operating characteristic (ROC) curve.ResultsThere were 176 ICU deaths in cohort 1 and 378 patients experienced all-cause mortality during 1 year of follow-up in cohort 2. The results of logistic regression revealed that SHR was associated with ICU death (odds ratio 2.92 [95% confidence interval 2.14–3.97] P < 0.001), and non-diabetic patients rather than diabetic patients showed an increased risk of ICU death. As per the Cox proportional hazards model, the high SHR group experienced a higher incidence of 1-year all-cause mortality (hazard ratio 1.55 [95% confidence interval 1.26–1.90] P < 0.001). Moreover, SHR had an incremental effect on various illness scores in predicting ICU all-cause mortality.ConclusionSHR is linked to ICU death and 1-year all-cause mortality in critically ill patients, and it has an incremental predictive value in different illness scores. Moreover, we found that non-diabetic patients, rather than diabetic patients, showed an increased risk of all-cause mortality.
Keywords
- all-cause mortality
- critically ill patients
- intensive care unit
- stress hyperglycemia ratio
- mortality
